| 154.98 3.17 (2.09%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 183.69 | 1-year : | 214.55 |
| Resists | First : | 157.27 | Second : | 183.69 |
| Pivot price | 146.38 |
|||
| Supports | First : | 133.82 | Second : | 119.33 |
| MAs | MA(5) : | 152.3 |
MA(20) : | 142.04 |
| MA(100) : | 124.64 |
MA(250) : | 114.85 |
|
| MACD | MACD : | 7.2 |
Signal : | 6.4 |
| %K %D | K(14,3) : | 88.1 |
D(3) : | 87.7  |
| RSI | RSI(14): 70.3 |
|||
| 52-week | High : | 157.27 | Low : | 91.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GILD ] has closed below upper band by 12.9%. Bollinger Bands are 93.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 157.09 - 158.19 | 158.19 - 159.05 |
| Low: | 149.42 - 150.57 | 150.57 - 151.48 |
| Close: | 153.46 - 155.26 | 155.26 - 156.66 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Sun, 15 Feb 2026
Assetmark Inc. Acquires 28,701 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Sun, 15 Feb 2026
Aberdeen Group plc Sells 160,874 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Sat, 14 Feb 2026
Gilead Sciences (GILD) Tops Earnings but Shares Fall on Guidance - GuruFocus
Sat, 14 Feb 2026
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Sat, 14 Feb 2026
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.82 - Yahoo Finance
Sat, 14 Feb 2026
BTC Capital Management Inc. Buys 64,668 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,240 (M) |
| Shares Float | 1,240 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 92.1 (%) |
| Shares Short | 22,970 (K) |
| Shares Short P.Month | 21,650 (K) |
| EPS | 6.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.34 |
| Profit Margin | 27.8 % |
| Operating Margin | 45.2 % |
| Return on Assets (ttm) | 12.5 % |
| Return on Equity (ttm) | 40.7 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 18.46 |
| Sales Per Share | 23.45 |
| EBITDA (p.s.) | 11.4 |
| Qtrly Earnings Growth | 143 % |
| Operating Cash Flow | 9,670 (M) |
| Levered Free Cash Flow | 8,030 (M) |
| PE Ratio | 23.58 |
| PEG Ratio | 0 |
| Price to Book value | 8.93 |
| Price to Sales | 6.6 |
| Price to Cash Flow | 19.87 |
| Dividend | 0.79 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|